MetLife Inc (MET)
Official siteFINANCIAL SERVICES • INSURANCE - LIFE • NYSE
Market Cap: $64.51B
Last updated: Nov 17, 2026 at 11:06 AM ET
MetLife Inc (MET) Stock Forecast
Analysts expect MetLife (MET) to earn $10.23 per share in the fiscal year ending Dec 31, 2026, on revenue of $79.45B. Of 18 analysts, 13 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 15 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 2.11, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 72% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 27.8% |
| Buy | 8 | 44.4% |
| Hold | 4 | 22.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 5.6% |
- Consensus
- Buy
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 9.3% and revenue estimates rise 4.5%.
- Fiscal year ending Dec 31, 2026
- $10.23
- EPS consensus, revenue $79.45B
- Fiscal year ending Dec 31, 2027
- $11.18
- EPS consensus, revenue $83.03B
- Next report
- Feb 2, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $10.23 | $10.02 to $10.48 | 17 | $79.45B | $78.59B to $80.61B | 8 |
| Dec 31, 2027 | $11.18 | $10.90 to $11.65 | 17 | $83.03B | $80.20B to $84.83B | 8 |
Quarterly Estimates
The EPS consensus falls from $2.65 for the quarter ending Dec 31, 2026 to $2.58 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.65 | $2.36 to $3.00 | 18 | $20.89B | $19.53B to $22.97B | 8 |
| Mar 31, 2027 | $2.58 | $2.39 to $2.78 | 11 | $20.45B | $20.09B to $20.66B | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 24 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 15 | 0 |
| Fiscal year ending Dec 31, 2027 | 6 | 2 |
| Quarter ending Mar 31, 2027 | 3 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.8% from $9.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $10.23 | $10.22 | $10.15 | $10.00 | $9.95 | +2.9% |
| Fiscal year ending Dec 31, 2027 | $11.18 | $11.16 | $11.15 | $11.13 | $11.09 | +0.8% |
| Quarter ending Mar 31, 2027 | $2.58 | $2.58 | $2.58 | $2.57 | $2.55 | +1.2% |
Frequently Asked Questions About MET
What is the MET stock forecast?
Consensus analyst estimates put MetLife's EPS at $10.23 for the fiscal year ending Dec 31, 2026, on revenue of $79.45B. The consensus rating from 18 analysts is Buy.
How do analysts rate MET stock?
Of 18 analysts covering MetLife, 5 rate it Strong Buy, 8 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MET next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $10.23, with estimates from $10.02 to $10.48 from 17 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.18, with estimates from $10.90 to $11.65 from 17 analysts.
What revenue do analysts expect from MetLife next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $79.45B, with estimates from $78.59B to $80.61B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $83.03B, with estimates from $80.20B to $84.83B.
How many analysts cover MET?
18 analysts rate MetLife stock, and 17 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MET pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts